



Docket:

NEB-150-PUS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Ming-Qun Xu

EXAMINER: William Moore

SERIAL NO.:

09/786,009

GROUP:

1652

FILED:

April 17, 2001

FOR:

Intein Mediated Peptide Ligation

RECEIVED

The Honorable Commissioner of

Patents

P.O. Box 1450

Alexandria, VA 22313-1450

JUN 0 9 2003

TECH CENTER 1600/2900

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §1.56 and §1.97, Applicants herewith submit the publications shown on the attached PTO-1449 form, for consideration by the Examiner in connection with the examination of the above-identified Application.

REMARKS

Publications, References CA-CD, were cited in the enclosed European Patent Office Search Report (Reference CE) dated May 13, 2003, received with the cited references by the undersigned attorney on May 22, 2003.

The relevance of each reference is apparent from the context of its citation by the EPO, and thus these items are being submitted simply because they were cited during the prosecution of a counterpart foreign application. The cited art is not believed material to the claims now pending in this Application. It is also



Ming-Qun Xu

U.S.S.N.: 09/786,009

Filed:

April 17, 2001

Page

2

RECEIVED

JUN 0 9 2003

TECH CENTER 1600/2900

believed that this submission satisfies the requirements of MPEP ξ 609 and 37 CFR ξ 1.56(a).

It is respectfully requested that each of the documents shown on the PTO-1449 Form be made of record in this Application.

RULE 97(e) CERTIFICATION

The undersigned attorney hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this paper.

FEE AUTHORIZATION

Please charge any fee associated with the submission of this paper to our Deposit Account No. 14-0740.

Respectfully submitted,

NEW ENGLAND BIOLABS, INC.

Date:

Harriet M. Strimpel, D.Phil.

(Reg No. 37008)

32 Tozer Road

Beverly, MA 01915

(978) 927-5054; Ext: 373

Ming-Qun Xu

U.S.S.N.:

09/786,009

Filed:

April 17, 2001

Page

3

I hereby certify that this INFORMATION DISCLOSURE STATEMENT, PTO-1449 FORM and REFERENCES DA-DC are being deposited with the United States Postal Service as first class mail in an envelope addressed to: ASSISTANT COMMISSIONER FOR PATENTS, P.O. Box 1450, Alexandria, VA 22313-1450 on this day of ________, 2003.

Melissa A. Jackson

| FORM PTO-1449 | | | ATTORNEY NO. | SERIAL NO. | |
|--|----------|---|---|----------------|--|
| | | | NEB-150-PUS | 09/786,009 | |
| INFORMATION DISCLOSURE STATEMENT | | | APPLICANTS: | | |
| The state of the s | | | Xu and Evans | | |
| | | | FILING DATE | GROUP NO. | |
| PATE | VU3 ; | | 17-Ap | | |
| JUN 0 5 2 | MA | Southworth, BioTech | niques 27:110-120 (1 | • | |
| | œ | Lykke-Andersen and Christiansen, Nucl. Acids Res. 26:5630-5635 (1998) | | | |
| | ∞ | Xu and Perler, EMBO Journal, 15:5146-5153 (1996) | | | |
| | œ | Severinov, et al., J. of Biological Chemistry 273:16205-16209 (1998) | | | |
| | Œ | May 13, 2003 Communication from European Patent Office enclosing | | | |
| | | European Search Report | | | |
| | | | | | |
| | | | | DECEIV | |
| | i İ | | | RECEIV | |
| **** | | | | JUN 0-9-21 | |
| | | | | TECH CENTED 16 | |
| | | | | TECH CENTER 16 | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | ! ! | | - X - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 | | |
| | Ī | | | | |
| | | | · · · · · · · · · · · · · · · · · · · | | |
| | | | | | |